These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 19368525)

  • 1. The use of agalsidase alfa enzyme replacement therapy in the treatment of Fabry disease.
    Morel CF; Clarke JT
    Expert Opin Biol Ther; 2009 May; 9(5):631-9. PubMed ID: 19368525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical observations on enzyme replacement therapy in patients with Fabry disease and the switch from agalsidase beta to agalsidase alfa.
    Lin HY; Huang YH; Liao HC; Liu HC; Hsu TR; Shen CI; Li ST; Li CF; Lee LH; Lee PC; Huang CK; Chiang CC; Lin SP; Niu DM
    J Chin Med Assoc; 2014 Apr; 77(4):190-7. PubMed ID: 24388678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enzyme replacement therapy for Anderson-Fabry disease.
    El Dib R; Gomaa H; Carvalho RP; Camargo SE; Bazan R; Barretti P; Barreto FC
    Cochrane Database Syst Rev; 2016 Jul; 7(7):CD006663. PubMed ID: 27454104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enzyme replacement therapy for Fabry disease: a systematic review of available evidence.
    Schaefer RM; Tylki-Szymańska A; Hilz MJ
    Drugs; 2009 Nov; 69(16):2179-205. PubMed ID: 19852524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and effectiveness of enzyme replacement therapy with agalsidase alfa in patients with Fabry disease: Post-marketing surveillance in Japan.
    Sasa H; Nagao M; Kino K
    Mol Genet Metab; 2019 Apr; 126(4):448-459. PubMed ID: 30803893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Agalsidase alfa: a review of its use in the management of Fabry disease.
    Keating GM
    BioDrugs; 2012 Oct; 26(5):335-54. PubMed ID: 22946754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Agalsidase alfa for the treatment of Fabry disease: new data on clinical efficacy and safety.
    Beck M
    Expert Opin Biol Ther; 2009 Feb; 9(2):255-61. PubMed ID: 19236256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safe and Successful Treatment With Agalsidase Beta During Pregnancy in Fabry Disease.
    Senocak Tasci E; Bicik Z
    Iran J Kidney Dis; 2015 Sep; 9(5):406-8. PubMed ID: 26338166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzyme replacement therapy of Fabry disease.
    Clarke JT; Iwanochko RM
    Mol Neurobiol; 2005 Aug; 32(1):43-50. PubMed ID: 16077182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study.
    Baehner F; Kampmann C; Whybra C; Miebach E; Wiethoff CM; Beck M
    J Inherit Metab Dis; 2003; 26(7):617-27. PubMed ID: 14707510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fabry nephropathy: a review - how can we optimize the management of Fabry nephropathy?
    Waldek S; Feriozzi S
    BMC Nephrol; 2014 May; 15():72. PubMed ID: 24886109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Fabry disease in Spain: first analysis of the response to enzyme replacement therapy].
    Rivera Gallego A; López Rodríguez M; Barbado Hernández FJ; Barba Romero MA; García de Lorenzo Y Mateos A; Pintos Morelle G;
    Med Clin (Barc); 2006 Oct; 127(13):481-4. PubMed ID: 17043001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with agalsidase beta during pregnancy in Fabry disease.
    Politei JM
    J Obstet Gynaecol Res; 2010 Apr; 36(2):428-9. PubMed ID: 20492401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on role of agalsidase alfa in management of Fabry disease.
    Ramaswami U
    Drug Des Devel Ther; 2011 Mar; 5():155-73. PubMed ID: 21552486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetics and Gene Therapy of Anderson-Fabry Disease.
    Simonetta I; Tuttolomondo A; Di Chiara T; Miceli S; Vogiatzis D; Corpora F; Pinto A
    Curr Gene Ther; 2018; 18(2):96-106. PubMed ID: 29618309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.
    Tsuboi K; Yamamoto H
    BMC Pharmacol Toxicol; 2017 Jun; 18(1):43. PubMed ID: 28592315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enzyme replacement therapy in Fabry disease: influence on cardiac manifestations.
    Caballero L; Climent V; Hernández-Romero D; Quintanilla MA; de la Morena G; Marín F
    Curr Med Chem; 2010; 17(16):1679-89. PubMed ID: 20345350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enzyme replacement therapy stabilizes obstructive pulmonary Fabry disease associated with respiratory globotriaosylceramide storage.
    Wang RY; Abe JT; Cohen AH; Wilcox WR
    J Inherit Metab Dis; 2008 Dec; 31 Suppl 2():S369-74. PubMed ID: 18937048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fabry disease, enzyme replacement therapy and the significance of antibody responses.
    Deegan PB
    J Inherit Metab Dis; 2012 Mar; 35(2):227-43. PubMed ID: 22037707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Home infusion program for Fabry disease: experience with agalsidase alfa in Argentina.
    Kisinovsky I; Cáceres G; Coronel C; Reisin R
    Medicina (B Aires); 2013; 73(1):31-4. PubMed ID: 23335703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.